{"id":"NCT03416179","sponsor":"Pfizer","briefTitle":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","officialTitle":"A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-20","primaryCompletion":"2020-06-05","completion":"2022-01-17","firstPosted":"2018-01-31","resultsPosted":"2021-06-25","lastUpdate":"2023-04-21"},"enrollment":730,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia, Myeloid, Acute"],"interventions":[{"type":"DRUG","name":"glasdegib","otherNames":["PF-04449913"]},{"type":"DRUG","name":"daunorubicin + cytarabine","otherNames":[]},{"type":"DRUG","name":"azacitidine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"glasdegib","otherNames":[]},{"type":"DRUG","name":"cytarabine","otherNames":[]},{"type":"PROCEDURE","name":"HSCT","otherNames":[]}],"arms":[{"label":"Arm A (Intensive Study)","type":"EXPERIMENTAL"},{"label":"Arm B (Intensive Study)","type":"PLACEBO_COMPARATOR"},{"label":"Arm A (Non-intensive study)","type":"EXPERIMENTAL"},{"label":"Arm B (Non-intensive study)","type":"PLACEBO_COMPARATOR"}],"summary":"Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).\n\nGlasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).","primaryOutcome":{"measure":"Intensive Study: Overall Survival (OS)","timeFrame":"Baseline up to 25 months","effectByArm":[{"arm":"Intensive Study: Glasdegib + Cytarabine + Daunorubicin","deltaMin":17.3,"sd":null},{"arm":"Intensive Study: Placebo + Cytarabine + Daunorubicin","deltaMin":20.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6579"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":149,"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Poland","Romania","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["37604981","31516032"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B1371019"]},"adverseEventsSummary":{"seriousAny":{"events":86,"n":198},"commonTop":["Anaemia","Nausea","Diarrhoea","Pyrexia","Constipation"]}}